scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0140-6736(98)08020-9 |
P698 | PubMed publication ID | 9788453 |
P50 | author | Paul Trouillas | Q11984910 |
Markku Kaste | Q16299732 | ||
Geoffrey A. Donnan | Q38545177 | ||
P2093 | author name string | S Davis | |
C Fieschi | |||
D Schneider | |||
D Meier | |||
E Bluhmki | |||
W Hacke | |||
V Larrue | |||
A Davalos | |||
R von Kummer | |||
E Diez-Tejedor | |||
P2860 | cites work | Tissue plasminogen activator for acute ischemic stroke | Q29619377 |
The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study | Q32048555 | ||
Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging | Q36714953 | ||
Variables associated with hospital arrival time after stroke: effect of delay on the clinical efficiency of early treatment | Q40903489 | ||
Evolving stroke and the ischemic penumbra | Q41152326 | ||
Hemorrhagic cerebral infarction--a prospective study | Q48371863 | ||
Stroke units versus general medical wards, I: twelve- and eighteen-month survival: a randomized, controlled trial | Q48554368 | ||
Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group | Q48913792 | ||
Thrombolytic therapy with streptokinase in acute ischemic stroke | Q48962264 | ||
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) | Q55063586 | ||
Hemorrhagic transformation in cerebral embolism | Q69605427 | ||
Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window | Q71568495 | ||
A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke St | Q73592931 | ||
Stroke unit versus general medical wards, II: neurological deficits and activities of daily living: a quasi-randomized controlled trial | Q74324126 | ||
P433 | issue | 9136 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | placebo | Q269829 |
thrombolysis | Q1931577 | ||
placebo-controlled trial | Q108853737 | ||
P304 | page(s) | 1245-1251 | |
P577 | publication date | 1998-10-01 | |
P1433 | published in | The Lancet | Q939416 |
P1476 | title | Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators | |
P478 | volume | 352 |
Q78137932 | 19th Meeting of the European Neurological Society. Milan, Italy, 5-9 June 1999. Abstracts |
Q92510859 | A Non-linear Association Between Total Small Vessel Disease Score and Hemorrhagic Transformation After Ischemic Stroke With Atrial Fibrillation and/or Rheumatic Heart Disease |
Q35608797 | A Parallel Thrombolysis Protocol with Nurse Practitioners As Coordinators Minimized Door-to-Needle Time for Acute Ischemic Stroke |
Q51665741 | A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice. |
Q55451286 | A Reduction in Time with Electronic Monitoring In Stroke (ARTEMIS): study protocol for a randomised multicentre trial. |
Q35243300 | A blinded, randomized study of L-arginine in small clot embolized rabbits |
Q34633083 | A case-control study of the effectiveness of tissue plasminogen activator on 6 month patients--reported outcomes and health care utilization |
Q48679156 | A comparison of 2 stroke devices: the new Aperio clot-removal device and the solitaire AB/FR. |
Q35175537 | A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy |
Q57021870 | A direct aspiration first pass technique with the new ARC catheter for thrombectomy of large vessel occlusion strokes: A multicenter study |
Q89577166 | A high neutrophil-to-lymphocyte ratio predicts hemorrhagic transformation of large atherosclerotic infarction in patients with acute ischemic stroke |
Q48937521 | A higher body temperature is associated with haemorrhagic transformation in patients with acute stroke untreated with recombinant tissue-type plasminogen activator (rtPA). |
Q36685755 | A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke |
Q41682251 | A nationwide prehospital stroke survey. |
Q48492472 | A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China |
Q42598719 | A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke |
Q37244463 | A pressuring issue: hemicraniectomy in patients with malignant middle cerebral artery infarction |
Q90645939 | ADAPT technique with ACE68 and ACE64 reperfusion catheters in ischemic stroke treatment: results from the PROMISE study |
Q48297394 | ASTRAL, DRAGON and SEDAN scores predict stroke outcome more accurately than physicians |
Q48278721 | Absent Filling of Ipsilateral Superficial Middle Cerebral Vein Is Associated With Poor Outcome After Reperfusion Therapy |
Q26796474 | Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke |
Q64889320 | Absolute blood eosinophil count could be a potential biomarker for predicting haemorrhagic transformation after intravenous thrombolysis for acute ischaemic stroke. |
Q31027291 | Actual diagnostic approach to the acute stroke patient |
Q73238461 | Acute Ischemic Stroke |
Q41626144 | Acute Ischemic Stroke Treatment Using Mechanical Thrombectomy: A Study of 137 Patients |
Q45023184 | Acute Ischemic Stroke and Thrombolysis Location: Comparing Telemedicine and Stroke Center Treatment Outcomes |
Q35678002 | Acute cerebral stroke imaging and brain perfusion with the use of high-concentration contrast media. |
Q39144348 | Acute endovascular treatment delivery to ischemic stroke patients transferred within a telestroke network: a retrospective observational study |
Q37079077 | Acute ischaemic stroke in patients aged 80 years and older: focus on the tolerability of thrombolytic agents |
Q33919326 | Acute ischemic stroke management |
Q33714948 | Acute ischemic stroke therapy |
Q73659561 | Acute ischemic stroke therapy |
Q37735842 | Acute ischemic stroke update |
Q38063337 | Acute ischemic stroke--from symptom recognition to thrombolysis |
Q31152112 | Acute ischemic stroke. Diagnostic imaging and interventional options |
Q38130551 | Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator. |
Q34964100 | Acute ischemic stroke: emergent evaluation and management |
Q36308664 | Acute stroke and diabetes |
Q33517464 | Acute stroke magnetic resonance imaging: current status and future perspective |
Q37564109 | Acute stroke therapy 1981-2009. |
Q28199361 | Acute therapy and prevention of stroke in spontaneous carotid dissection |
Q48642241 | Acute-stage evolution of watershed infarction assessed on diffusion-weighted MR imaging |
Q41769410 | Adapting the computed tomography criteria of hemorrhagic transformation to stroke magnetic resonance imaging |
Q47326375 | Adjuvant revascularization of intracranial artery occlusion with angioplasty and/or stenting |
Q48311963 | Administration of tissue plasminogen activator without coagulation results in a Chinese population. |
Q30950281 | Advanced imaging application for acute ischemic stroke |
Q36881065 | Advanced imaging improves prediction of hemorrhage after stroke thrombolysis |
Q34212681 | Advanced neuroimaging in stroke patients: prediction of tissue fate and hemorrhagic transformation |
Q33278117 | Advances in ischemic stroke treatment: neuroprotective and combination therapies |
Q37896682 | Advances in stroke care and research in 2010. |
Q36273735 | Advances in thrombolytics and mechanical devices for treatment of acute ischemic stroke |
Q37107770 | Adverse outcome of early recurrent ischemic stroke secondary to atrial fibrillation after repeated systemic thrombolysis |
Q37540778 | Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial |
Q33213041 | Alteplase and ischaemic stroke: have new reviews of old data helped? |
Q36484897 | Alteplase for acute ischemic stroke |
Q36172947 | Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance |
Q38271386 | Alteplase for the treatment of acute ischaemic stroke: a NICE single technology appraisal; an evidence review group perspective. |
Q38261206 | Alteplase in acute ischemic stroke: putting the guidelines into practice |
Q48304361 | Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study |
Q38040823 | Alteplase: a review of its use in the management of acute ischaemic stroke |
Q91741423 | Altered expression of long noncoding RNAs in peripheral blood mononuclear cells in patients with impaired leptomeningeal collaterals after acute anterior large vessel occlusions |
Q73090350 | Alternative strategies for stroke care: a prospective randomised controlled trial |
Q51021136 | An In Vitro Assay for Sonothrombolysis Based on the Spectrophotometric Measurement of Clot Thickness. |
Q40523644 | An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke |
Q39217717 | Analysis of risk factors of hemorrhagic transformation after acute ischemic stroke: cerebral microbleeds do not correlate with hemorrhagic transformation |
Q34255837 | Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria |
Q83396816 | Angioedema after tPA: what neurointensivists should know |
Q61444132 | Angioedema after thrombolysis with tissue plasminogen activator: an airway emergency |
Q54960968 | Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator. |
Q36172633 | Anthropometric approximation of body weight in unresponsive stroke patients |
Q38760549 | Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis. |
Q35752603 | Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q34441586 | Antithrombotic therapy for prevention and treatment of ischemic stroke |
Q35967397 | Antithrombotic trials in acute ischaemic stroke: a selective review |
Q53235150 | Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? No. |
Q35108612 | Are the current MRI criteria using the DWI-FLAIR mismatch concept for selection of patients with wake-up stroke to thrombolysis excluding too many patients? |
Q35823610 | Arterial ischaemic stroke in children |
Q36846675 | Artery reopening is required for the neurorestorative effects of angiotensin modulation after experimental stroke |
Q48863162 | Aspects of stroke imaging. |
Q97527313 | Aspiration Thrombectomy for Posterior Circulation Stroke: A Systematic Review and Meta-Analysis |
Q49026481 | Assessment of brain tissue viability in acute ischemic stroke by BOLD MRI. |
Q33194490 | Assessment of the Patient with Hyperacute Stroke: Imaging and Therapy |
Q35884063 | Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial |
Q89599757 | Association between non-high-density lipoprotein cholesterol and haemorrhagic transformation in patients with acute ischaemic stroke |
Q46482111 | Association of CT perfusion parameters with hemorrhagic transformation in acute ischemic stroke |
Q47963971 | Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials |
Q40887679 | Association of time on outcome after intravenous thrombolysis in the elderly in a telestroke network. |
Q35074272 | Astrocytes and stroke: networking for survival? |
Q37070706 | Atrial fibrillation is a predictor of in-hospital mortality in ischemic stroke patients |
Q33365938 | Avoiding time delay in acute stroke management. Data analysis of the Austrian Stroke Unit Registry |
Q47784147 | Baseline serum glucose concentration and symptomatic haemorrhagic transformation in non-diabetic stroke patients treated by intravenous thrombolysis |
Q39685305 | Bed rest or mobilization after rt-PA? A case-crossover study of factors influencing clinical decision making in stroke services |
Q43767033 | Benefit of thrombolysis for stroke is maintained around the clock: results from the SITS-EAST Registry. |
Q36898606 | Beyond intravenous thrombolysis |
Q36297030 | Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis. |
Q33863549 | Blood Pressure and Penumbral Sustenance in Stroke from Large Vessel Occlusion. |
Q46094875 | Blood glucose in acute stroke |
Q36515581 | Blood pressure lowering in acute phase of stroke: latest evidence and clinical implications |
Q89699511 | Blood-brain barrier integrity of stroke patients presenting in an extended time window |
Q50042848 | Blood-ocular barrier disruption in acute stroke patients |
Q44416795 | Body temperature, blood infection parameters, and outcome of thrombolysis-treated ischemic stroke patients |
Q38254946 | Brain endothelial cell specific integrins and ischemic stroke |
Q36736801 | Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications |
Q37029956 | Brain perfusion CT: principles, technique and clinical applications. |
Q36262669 | Brain tissue salvage in acute stroke |
Q48762513 | C-reactive protein after stroke in arterial hypertension |
Q90626852 | CJEM Debate Series: #TPA should be the initial treatment in eligible patients presenting with an acute ischemic stroke |
Q45092276 | CT interpretation by ASPECTS in hyperacute ischemic stroke predicting functional outcomes |
Q37267695 | CT perfusion-guided patient selection for endovascular recanalization in acute ischemic stroke: a multicenter study. |
Q47220650 | Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches |
Q35574076 | Can the time window for administration of thrombolytics in stroke be increased? |
Q48486493 | Cerebellar vermis: a vulnerable location of remote brain haemorrhages after thrombolysis for ischaemic stroke |
Q35908363 | Cerebral Blood Volume ASPECTS Is the Best Predictor of Clinical Outcome in Acute Ischemic Stroke: A Retrospective, Combined Semi-Quantitative and Quantitative Assessment |
Q46850012 | Cerebral edema in acute ischemic stroke patients treated with intravenous thrombolysis |
Q33794874 | Cerebral hemorrhagic complications of thrombolytic therapy |
Q38700477 | Cerebral hyperperfusion on arterial spin labeling MRI after reperfusion therapy is related to hemorrhagic transformation |
Q55342088 | Cerebral microbleeds shouldn't dictate treatment of acute stroke: a retrospective cohort study evaluating risk of intracerebral hemorrhage. |
Q42956821 | Cerebral β-amyloid detected by Pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage |
Q79125959 | Characteristics of the National Institute of Health Stroke Scale: Results from a Population-Based Stroke Cohort at Baseline and after One Year |
Q26864892 | Chinese guidelines for endovascular management of ischemic cerebrovascular diseases |
Q37291553 | Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis |
Q34280852 | Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). |
Q54950942 | Clinical and radiological factors associated with unfavorable outcome after intravenous thrombolysis in patients with mild ischemic stroke. |
Q64066779 | Clinical efficacy of collateral circulation in the evaluation of endovascular treatment for acute internal carotid artery occlusion |
Q38195198 | Clinical experience with the pREset stent retriever for the treatment of acute ischemic stroke--a review of 271 consecutive cases. |
Q47741730 | Clinical implication of hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator |
Q41016421 | Clinical outcomes of patients with acute minor stroke receiving rescue IA therapy following early neurological deterioration. |
Q36496990 | Clinical pharmacological issues in the development of acute stroke therapies |
Q64104985 | Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants - A systematic review |
Q33299284 | Clinical review: Imaging in ischaemic stroke--implications for acute management |
Q34377022 | Clinical thrombolysis in stroke |
Q38243696 | Clinical trials in acute ischemic stroke |
Q57156101 | Cohort profile: Thrombolysis in Ischemic Stroke Patients (TRISP): a multicentre research collaboration |
Q86758826 | Cohort-Based Identification of Predictors of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis |
Q48362661 | Combined full-dose IV and endovascular thrombolysis in acute ischaemic stroke |
Q53546600 | Combined intravenous and intraarterial revascularization therapy using MRI perfusion/diffusion mismatch selection for acute ischemic stroke at 3-6 h after symptom onset. |
Q52206915 | Common sense, nonsense and statistics. |
Q35088083 | Comparative effectiveness of standard care with IV thrombolysis versus without IV thrombolysis for mild ischemic stroke |
Q45126061 | Comparison of 8 scores for predicting symptomatic intracerebral hemorrhage after IV thrombolysis. |
Q34486638 | Comparison of Therapeutic Effect of Recombinant Tissue Plasminogen Activator by Treatment Time after Onset of Acute Ischemic Stroke |
Q43506227 | Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. |
Q48950181 | Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke |
Q33693506 | Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). |
Q41045620 | Complete reperfusion is required for maximal benefits of mechanical thrombectomy in stroke patients. |
Q34985409 | Comprehensive CT Evaluation in Acute Ischemic Stroke: Impact on Diagnosis and Treatment Decisions |
Q33517016 | Computed tomography in acute ischemic stroke |
Q48500154 | Computed tomography perfusion imaging in acute stroke |
Q40539896 | Computed tomography perfusion-based thrombolysis in wake-up stroke |
Q46326037 | Contact Aspiration with the New ARC Catheter for Thrombectomy of Acute Ischemic Stroke: Single-Center Results |
Q37676388 | Contrast staining on CT after DSA in ischemic stroke patients progresses to infarction and rarely hemorrhages |
Q48289741 | Contrast-enhanced MR imaging in acute ischemic stroke: T2* measures of blood-brain barrier permeability and their relationship to T1 estimates and hemorrhagic transformation. |
Q34271967 | Controversies about tissue plasminogen activator: extending the window of therapy |
Q34180151 | Cost-Effectiveness of Recombinant Tissue Plasminogen Activator in the Management of Acute Ischemic Stroke: A Systematic Review |
Q77146377 | Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective |
Q47654016 | Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran. |
Q48716156 | Could thrombolytic approaches in acute stroke benefit from stringent selection criteria? |
Q38720694 | Critical Care of Brain Reperfusion. |
Q34566641 | Critical care of acute ischemic stroke |
Q51021192 | Curitiba acute ischemic stroke protocol: a university hospital and EMS initiative in a large Brazilian city. |
Q38475374 | Current and future bioanalytical approaches for stroke assessment |
Q36059382 | Current management of acute ischemic stroke. Part 1: Thrombolytics and the 3-hour window |
Q30414441 | Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke |
Q57482501 | Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke |
Q52620336 | Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review. |
Q45740384 | Death, dependency and health status 90 days following hospital admission for acute stroke in NSW. |
Q40530815 | Decreased serum PCSK9 levels after ischaemic stroke predict worse outcomes |
Q53527989 | Defining post-stroke recovery: implications for design and interpretation of drug trials. |
Q34567097 | Delayed combination therapy of local brain hypothermia and decompressive craniectomy on acute stroke outcome in rat. |
Q36917102 | Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats |
Q35172350 | Design of future acute-stroke treatment trials |
Q37489895 | Desmoteplase |
Q53447862 | Detection and significance of incidental unruptured cerebral aneurysms in patients undergoing intravenous thrombolysis for acute ischemic stroke. |
Q38223429 | Detection of Early Ischemic Changes in Noncontrast CT Head Improved with "Stroke Windows". |
Q36536220 | Determinants of outcome in patients eligible for thrombolysis for ischemic stroke. |
Q36052939 | Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument |
Q31161803 | Developments in neuroimaging for acute ischemic stroke: diagnostic and clinical trial applications |
Q28085439 | Diagnosis and management of acute ischemic stroke: speed is critical |
Q33609391 | Diagnosis and treatment of ischemic stroke |
Q58619430 | Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke |
Q38691109 | Direct Microsurgical Embolectomy for Acute Occlusion of the Internal Carotid Artery and Middle Cerebral Artery |
Q58594064 | Direct Thrombectomy versus Bridging for Patients with Emergent Large-Vessel Occlusions |
Q53450606 | Direct thrombus retrieval using the reperfusion catheter of the penumbra system: forced-suction thrombectomy in acute ischemic stroke. |
Q35539636 | Disability-adjusted life years analysis: implications for stroke research. |
Q48297924 | Distal hyperintense vessel sign is associated with neurological deterioration in acute ischaemic stroke |
Q37626539 | Distinctive patterns on CT angiography characterize acute internal carotid artery occlusion subtypes. |
Q48257270 | Do lacunar strokes benefit from thrombolysis? Evidence from the Registry of the Canadian Stroke Network |
Q37072580 | Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke can Cause Inferior Myocardial Infarction? |
Q36620631 | Does preexisting antiplatelet treatment influence postthrombolysis intracranial hemorrhage in community-treated ischemic stroke patients? An observational study |
Q43575338 | Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke? |
Q43528638 | Does time of day or physician experience affect outcome of acute ischemic stroke patients treated with thrombolysis? A study from Finland |
Q33801602 | Dosage Calculation for Intravenous Thrombolysis of Ischemic Stroke: To Weigh or to Estimate? |
Q34093258 | Doubts, fears and misconceptions. What is the future of thrombolysis in acute stroke? |
Q48464277 | Dramatically reducing imaging-to-recanalization time in acute ischemic stroke: making choices |
Q35944682 | Drip, Ship, and On-Demand Endovascular Therapy for Acute Ischemic Stroke |
Q35027655 | Drug-induced iatrogenic intraparenchymal hemorrhage |
Q43473876 | Dual-energy CT immediately after endovascular stroke intervention: prognostic implications |
Q34166302 | Dual-phase CT collateral score: a predictor of clinical outcome in patients with acute ischemic stroke. |
Q37209587 | Dynamic change of neutrophil to lymphocyte ratio and hemorrhagic transformation after thrombolysis in stroke |
Q34845393 | Dynamic contrast-enhanced computed tomography of acute ischemic stroke: CTA and CTP. |
Q74452298 | ECASS II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II |
Q74452293 | ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II |
Q93918248 | ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II |
Q93918251 | ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II |
Q95283203 | ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II |
Q56971433 | EU-geförderte Therapiestudie WAKE-UP |
Q48317096 | Early Blood Brain Barrier Changes in Acute Ischemic Stroke: A Sequential MRI Study |
Q87667920 | Early CT Score to establish stroke treatment |
Q48968366 | Early CT perfusion mismatch in acute stroke is not time-dependent but relies on collateralization grade |
Q51687433 | Early Use of Statin in Patients Treated with Alteplase for Acute Ischemic Stroke. |
Q84502139 | Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial |
Q53182520 | Early computed tomography signs as early predictors of hemorrhagic transformation under heparinization in patients with cardiogenic embolism. |
Q43846043 | Early major worsening in ischemic stroke: predictors and outcome |
Q48181753 | Early recanalisation in acute ischaemic stroke saves tissue at risk defined by MRI. |
Q92644085 | Early seizures after ischemic stroke: focus on thrombolysis |
Q48636297 | Eating difficulties among patients 3 months after stroke in relation to the acute phase |
Q48629293 | Eating difficulties among stroke patients in the acute state: a descriptive, cross-sectional, comparative study |
Q48136783 | Effect modification and ischaemic stroke treatment |
Q89512621 | Effect of Argatroban Combined With Dual Antiplatelet Therapy on Early Neurological Deterioration in Acute Minor Posterior Circulation Ischemic Stroke |
Q48670915 | Effect of Intracranial Atherosclerotic Disease on Endovascular Treatment for Patients with Acute Vertebrobasilar Occlusion. |
Q97425304 | Effect of haemoglobin levels on outcome in intravenous thrombolysis-treated stroke patients |
Q37271601 | Effect of prior medical treatments on ischemic stroke severity and outcome. |
Q26823902 | Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials |
Q36099907 | Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials |
Q38703871 | Effects of increasing IV tPA-treated stroke mimic rates at CT-based centers on clinical outcomes |
Q35181092 | Effects of thrombolysis for acute stroke in patients with pre-existing disability |
Q38879635 | Efficacy and Safety Evaluation on Arterial Thrombolysis in Treating Acute Cerebral Infarction |
Q64096026 | Efficacy and Safety of Endovascular Treatment in Patients with Internal Carotid Artery Occlusion and Collateral Middle Cerebral Artery Flow |
Q90355035 | Efficacy and Safety of Intravenous Thrombolysis in Patients with Unknown Onset Stroke: A Meta-Analysis |
Q98177550 | Efficacy and Safety of Intravenous Thrombolysis on Acute Branch Atheromatous Disease: A Retrospective Case-Control Study |
Q35772351 | Efficacy and Safety of Mechanical Thrombectomy in Treating Acute Ischemic Stroke: A Meta Analysis |
Q37765756 | Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset |
Q47147347 | Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis. |
Q37301824 | Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. |
Q59135176 | Efficacy evaluation of reteplase in a novel canine acute pulmonary thromboembolism model developed by minimally invasive surgery and digital subtraction angiography |
Q33978307 | Efficacy of recombinant annexin 2 for fibrinolytic therapy in a rat embolic stroke model: a magnetic resonance imaging study |
Q87354559 | Efficacy of systemic thrombolysis within 4.5 h from stroke symptom onset: a single-centre clinical and diffusion-perfusion 3T MRI study |
Q39761831 | Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience |
Q96816794 | Elevated glucose is associated with hemorrhagic transformation after mechanical thrombectomy in acute ischemic stroke patients with severe pretreatment hypoperfusion |
Q92116253 | Elevation of high-sensitivity cardiac troponin T at admission is associated with increased 3-month mortality in acute ischemic stroke patients treated with thrombolysis |
Q48446143 | Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor |
Q48458092 | Emergency and critical care management of acute ischaemic stroke |
Q46752696 | Emergency cervical internal carotid artery stenting in combination with intracranial thrombectomy in acute stroke |
Q30976444 | Emergency imaging of cerebrovascular accidents |
Q30588194 | Emergency management of ischemic stroke. |
Q42007077 | Emergency revascularization for acute main-trunk occlusion in the anterior circulation |
Q34511312 | Emergency stroke management: a new era. |
Q46111613 | Emergency treatment of acute ischemic stroke: expanding the time window |
Q40290208 | Emergent cervical surgical embolectomy for extracranial internal carotid artery occlusion |
Q39930533 | Endovascular Management of Tandem Occlusion Stroke Related to Internal Carotid Artery Dissection Using a Distal to Proximal Approach: Insight from the RECOST Study. |
Q39241871 | Endovascular Stroke Treatment of Nonagenarians. |
Q89846974 | Endovascular Treatment of Very Elderly Patients Aged ≥90 With Acute Ischemic Stroke |
Q48453730 | Endovascular acute stroke treatment performed by vascular interventional radiologists: is it safe and efficacious? |
Q41359514 | Endovascular mechanical recanalization of acute ischaemic stroke in octogenarians |
Q40912814 | Endovascular mechanical thrombectomy in basilar artery occlusion: variables affecting recanalization and outcome |
Q46713110 | Endovascular recanalization of complete subacute to chronic atherosclerotic occlusions of intracranial arteries |
Q33562121 | Endovascular stroke treatment in a small-volume stroke center |
Q37828312 | Endovascular stroke treatment today. |
Q37269850 | Endovascular therapy for acute ischemic stroke |
Q38293873 | Endovascular therapy for acute ischemic stroke is indicated and evidence based: a position statement |
Q33735191 | Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials: A report from the Working Group of International Congress of Interventional Neurology |
Q48452336 | Endovascular treatment of acute intracerebral artery occlusions with the solitaire stent: single-centre experience with 108 recanalization procedures |
Q35689108 | Endovascular treatment of cerebrovascular diseases and intracranial neoplasms |
Q37172019 | Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation |
Q44051982 | Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study |
Q35956310 | Erythropoietin: novel approaches to neuroprotection in human brain disease |
Q36720328 | Established treatments for acute ischaemic stroke |
Q34117195 | European Stroke Initiative (EUSI) recommendations for stroke management. The European Stroke Initiative Writing Committee |
Q34517458 | Evaluation and management of acute ischemic stroke |
Q53581676 | Evaluation of a new Spin-echo diffusion-weighted sequence on a 0.35 T open magnetic resonance imaging (MRI)-system: first experiences within 3 h after acute stroke. |
Q40224799 | Evaluation of the recombinant tissue plasminogen activator pretreatment in acute stroke patients with large vessel occlusions treated with the direct bridging approach. Is it worth the effort? |
Q36556403 | Evidence, education and practice. |
Q73111221 | Evidence-based emergency medicine: updates, feedback, and links |
Q30844897 | Evidence-based neuroimaging in acute ischemic stroke |
Q74261521 | Evidence-based treatment of patients with ischemic cerebrovascular disease |
Q33688138 | Evolution of the thrombolytic treatment window for acute ischemic stroke |
Q36465286 | Evolving paradigms for neuroprotection: molecular identification of ischemic penumbra |
Q37436384 | Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. |
Q36720333 | Experimental treatments for acute ischaemic stroke |
Q37034881 | Exploring gender distribution in patients with acute stroke: A multi-national approach |
Q89494628 | Expression of Cytokines and Chemokines as Predictors of Stroke Outcomes in Acute Ischemic Stroke |
Q37343414 | Extended Use of Hypothermia in Elderly Patients with Malignant Cerebral Edema as an Alternative to Hemicraniectomy |
Q90248089 | External Validation and Modification of the EDEMA Score for Predicting Malignant Brain Edema After Acute Ischemic Stroke |
Q35651846 | External validation of the SEDAN score: The real world practice of a single center. |
Q43076288 | FAST positive does not always mean stroke. |
Q48132450 | Factors Mediating Outcome After Stroke: Gender, Thrombolysis, and Their Interaction. |
Q30638020 | Factors influencing haemorrhagic transformation in ischaemic stroke. |
Q48114830 | Feasibility of Permanent Stenting with Solitaire FR as a Rescue Treatment for the Reperfusion of Acute Intracranial Artery Occlusion |
Q34603396 | Fibrinolysis and Beyond: Bridging the Gap between Local and Systemic Clot Removal |
Q36382572 | Fibrinolytic treatment for acute ischaemic stroke |
Q38680151 | Focal Low and Global High Permeability Predict the Possibility, Risk, and Location of Hemorrhagic Transformation following Intra-Arterial Thrombolysis Therapy in Acute Stroke |
Q36104057 | Frequency and predictors of symptomatic intracranial hemorrhage after intravenous thrombolysis for acute ischemic stroke in a Brazilian public hospital. |
Q64108422 | Frequency of Hemorrhage on Follow Up Imaging in Stroke Patients Treated With rt-PA Depending on Clinical Course |
Q92595056 | Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial |
Q73906894 | Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators |
Q44742128 | Graded reoxygenation with chemical inhibition of oxidative phosphorylation improves posthypoxic recovery in murine hippocampal slices |
Q34170539 | Graphic reanalysis of the two NINDS-tPA trials confirms substantial treatment benefit |
Q36561350 | Gray-Matter Volume Estimate Score: A Novel Semi-Automatic Method Measuring Early Ischemic Change on CT. |
Q91697958 | Guidelines for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen Activator), the Third Edition, March 2019: A Guideline from the Japan Stroke Society |
Q37640881 | Haemorrhagic Transformation after Ischaemic Stroke in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants |
Q90633783 | Haemorrhagic transformation following ischaemic stroke: A retrospective study |
Q33249571 | Halving effort in acute stroke trials |
Q37531421 | Health Aid Is Allocated Efficiently, But Not Optimally: Insights From A Review Of Cost-Effectiveness Studies |
Q94456735 | Health Utility Weighting of the Modified Rankin Scale: A Systematic Review and Meta-analysis |
Q48558753 | Hemiplegia and thrombolysis |
Q35752364 | Hemorrhage Rates and Outcomes When Using up to 100 mg Intra-Arterial t-PA for Thrombolysis in Acute Ischemic Stroke |
Q43505769 | Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation |
Q36515347 | Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas |
Q36914630 | Hemorrhagic transformation: a review of the rate of hemorrhage in the major clinical trials of acute ischemic stroke |
Q33842161 | Hemostasis and alterations of the central nervous system |
Q90381934 | High Neutrophil-to-Lymphocyte Ratio Predicts Hemorrhagic Transformation in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis |
Q92537389 | High Neutrophil-to-Platelet Ratio Is Associated With Hemorrhagic Transformation in Patients With Acute Ischemic Stroke |
Q30671155 | Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. |
Q36638843 | How temporal evolution of intracranial collaterals in acute stroke affects clinical outcomes. |
Q38920992 | How to Measure Recovery? Revisiting Concepts and Methods for Stroke Studies |
Q90472658 | How to Set up a Thrombectomy Service : The St. Petersburg Experience |
Q45348024 | How to identify stroke mimics in patients eligible for intravenous thrombolysis? |
Q48827756 | Hyperdensity on non-contrast CT immediately after intra-arterial revascularization |
Q38044504 | IST-3: no pragmatic answers |
Q36405870 | IV thrombolysis in very severe and severe ischemic stroke: Results from the SITS-ISTR Registry |
Q42196783 | Identification of Reversible Disruption of the Human Blood-Brain Barrier Following Acute Ischemia |
Q38051668 | Identifying implications of thrombolysis for stroke rehabilitation: knowledge gaps in current research. |
Q40394460 | Identifying patients at risk of acute symptomatic seizure after ischemic stroke |
Q47098542 | If Time Is Brain Where Is the Improvement in Prehospital Time after Stroke? |
Q37679163 | Imaging Oxygen Metabolism In Acute Stroke Using MRI. |
Q47586925 | Imaging assessment of acute ischaemic stroke: a review of radiological methods. |
Q59858865 | Imaging of acute stroke |
Q30831710 | Imaging of acute stroke prior to treatment: current practice and evolving techniques |
Q36379591 | Imaging of cerebral ischemic edema and neuronal death. |
Q30904038 | Imaging-based management of acute ischemic stroke patients: current neuroradiological perspectives |
Q33978760 | Imaging-based treatment selection for intravenous and intra-arterial stroke therapies: a comprehensive review |
Q47300027 | Impact of Anesthesia on the Outcome of Acute Ischemic Stroke after Endovascular Treatment with the Solitaire Stent Retriever. |
Q33567258 | Impact of Baseline Ischemia on Outcome in Older Patients Undergoing Endovascular Therapy for Acute Ischemic Stroke |
Q64107318 | Impact of Emergent Cervical Carotid Stenting in Tandem Occlusion Strokes Treated by Thrombectomy: A Review of the TITAN Collaboration |
Q37052977 | Impact of Target Arterial Residual Stenosis on Outcome After Endovascular Revascularization |
Q48592895 | Impact of body mass index on outcome in stroke patients treated with intravenous thrombolysis |
Q49335726 | Impact of collateral circulation status on favorable outcomes in thrombolysis treatment: A systematic review and meta-analysis |
Q35414185 | Impact of diffusion-weighted imaging lesion volume on the success of endovascular reperfusion therapy |
Q49223257 | Impact of intravenous thrombolysis on length of hospital stay in cases of acute ischemic stroke |
Q39570573 | Impact of leukoaraiosis on parenchymal hemorrhage in elderly patients treated with thrombolysis |
Q35084483 | Impact of sex in stroke thrombolysis: a coarsened exact matching study |
Q55024296 | Impact of smoking on stroke outcome after endovascular treatment. |
Q58698188 | Impact of the Thrombectomy Trials on the Management and Outcome of Large Vessel Stroke: Data From the Lyon Stroke Center |
Q39102006 | Impact of time-to-reperfusion on outcome in patients with poor collaterals. |
Q85597035 | Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients |
Q84610115 | Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR |
Q48228152 | Implementation of Telemedicine and Stroke Network in thrombolytic administration: comparison between walk-in and referred patients. |
Q97692853 | Improved collateral flow and reduced damage after remote ischemic perconditioning during distal middle cerebral artery occlusion in aged rats |
Q48863199 | Improved outcomes in stroke thrombolysis with pre-specified imaging criteria. |
Q47170593 | Improving Cerebral Blood Flow after Arterial Recanalization: A Novel Therapeutic Strategy in Stroke |
Q37610822 | Improving diagnostic value of CT examinations in hyperacute ischemic stroke |
Q74254446 | In response |
Q38677213 | In-hospital ischaemic stroke treated with intravenous thrombolysis or mechanical thrombectomy |
Q41458166 | Increased globulin and its association with hemorrhagic transformation in patients receiving intra-arterial thrombolysis therapy |
Q39201905 | Infarct topography and functional outcomes. |
Q47595033 | Influence of Renal Function on Treatment Results after Stroke Thrombectomy |
Q64105269 | Influence of Sex on Stroke Prognosis: A Demographic, Clinical, and Molecular Analysis |
Q41481263 | Influence of glycaemic control on the outcomes of patients treated by intravenous thrombolysis for cerebral ischaemia |
Q41293946 | Influence of neurologists' experience on the outcome of patients treated by intravenous thrombolysis for cerebral ischaemia |
Q60597543 | Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke |
Q35024112 | Influence of racial differences on outcomes after thrombolytic therapy in acute ischemic stroke |
Q92421734 | Initial Experience in Direct Aspiration Thrombectomy Using a Novel 0.071-Inch Aspiration Catheter |
Q53250607 | Initial experience with a self-expanding retrievable stent for recanalization of large vessel occlusions in acute ischemic stroke. |
Q48173064 | Initial experience with the Penumbra Stroke System for recanalization of large vessel occlusions in acute ischemic stroke |
Q74654805 | Innovative Strategies in the Management of Acute Stroke |
Q34517445 | Innovative strategies in the management of acute stroke |
Q38860911 | Interhospital Transfer of Neurosurgical Patients: Implications of Timing on Hospital Course and Clinical Outcomes |
Q33653013 | Interventional neurology: a personal road map |
Q90358573 | Intra-Arterial Tissue Plasminogen Activator Is a Safe Rescue Therapy with Mechanical Thrombectomy |
Q89395791 | Intra-arterial Thrombolysis in Second Trimester of Pregnancy. A Case Report |
Q48969911 | Intra-arterial adjuvant tirofiban after unsuccessful intra-arterial thrombolysis of acute ischemic stroke: preliminary experience in 16 patients |
Q43560267 | Intra-arterial stroke therapy: patient safety considerations |
Q34261689 | Intra-arterial therapy as a rescue strategy after clinically failed intravenous thrombolysis may increase the likelihood of a good outcome in patients with severe ischaemic stroke. A retrospective two centre study |
Q48821499 | Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke |
Q48920928 | Intra-arterial thrombolysis in acute ischaemic stroke |
Q35777379 | Intra-arterial thrombolysis in acute ischemic stroke: a review of pharmacologic approaches |
Q45214996 | Intra-arterial thrombolysis in patients treated with warfarin |
Q36256072 | Intra-arterial thrombolysis of a distal internal carotid artery occlusion in an adolescent |
Q53460532 | Intra-arterial thrombolysis using rt-PA in patients with acute stroke due to vessel occlusion of anterior and/or posterior cerebral circulation. |
Q83371509 | Intra-arterial thrombolysis within three hours of stroke onset in middle cerebral artery strokes |
Q30470195 | Intra-arterial versus intra-venous thrombolysis within and after the first 3 hours of stroke onset |
Q84148337 | Intra-arterial vs intra-venous. Thrombolysis for anterior cerebral occlusion |
Q73659570 | Intracerebral hemorrhage |
Q33184858 | Intracerebral hemorrhage. |
Q50050498 | Intracranial Internal Carotid Artery Wall Calcification in Ischemic Strokes Treated with Thrombolysis. |
Q89965051 | Intracranial Stenting After Failed Thrombectomy in Patients With Moderately Severe Stroke: A Multicenter Cohort Study |
Q36302531 | Intracranial thrombectomy using the Solitaire stent: a historical vignette |
Q47214723 | Intracranial thrombus extent predicts clinical outcome, final infarct size and hemorrhagic transformation in ischemic stroke: the clot burden score |
Q90599551 | Intravenous Administration of Standard Dose Tirofiban after Mechanical Arterial Recanalization is Safe and Relatively Effective in Acute Ischemic Stroke |
Q35739435 | Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials |
Q26796477 | Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom Onset |
Q36956762 | Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta-analysis of 19 Studies |
Q36048610 | Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment. |
Q42380272 | Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice. |
Q64085121 | Intravenous Thrombolysis in Posterior Circulation Stroke |
Q36255802 | Intravenous Tissue Plasminogen Activator Improves the Outcome in Very Elderly Korean Patients with Acute Ischemic Stroke |
Q40065087 | Intravenous alteplase versus rescue endovascular procedure in patients with proximal middle cerebral artery occlusion |
Q28275566 | Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial |
Q37314662 | Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. |
Q64905047 | Intravenous fibrinolysis plus endovascular thrombectomy versus direct endovascular thrombectomy for anterior circulation acute ischemic stroke: clinical and infarct volume results. |
Q33785353 | Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis |
Q35490096 | Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients |
Q37209014 | Intravenous rt-PA versus endovascular therapy for acute ischemic stroke |
Q50072337 | Intravenous rtPA versus mechanical thrombectomy in acute ischemic stroke: A historical cohort in Joinville, Brazil |
Q52150474 | Intravenous thrombolysis and intra-arterial interventions in acute ischemic stroke: Italian Stroke Organisation (ISO)-SPREAD guidelines. |
Q38407128 | Intravenous thrombolysis and three-year ischemic stroke mortality |
Q39034824 | Intravenous thrombolysis before endovascular therapy for large vessel strokes can lead to significantly higher hospital costs without improving outcomes |
Q48766417 | Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients ≥ 80 years of age. |
Q37979874 | Intravenous thrombolysis for acute ischemic stroke in Asia |
Q64326777 | Intravenous thrombolysis for acute ischemic stroke in Greece: the Safe Implementation of Thrombolysis in Stroke registry 15-year experience |
Q34262372 | Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms |
Q39394485 | Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries |
Q36227035 | Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study |
Q38225341 | Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications |
Q40134099 | Intravenous thrombolysis in patients aged more than 80 years in the three rural hospitals in southeast Poland: an observational study |
Q64892044 | Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results. |
Q31108563 | Intravenous thrombolysis is more safe and effective for posterior circulation stroke: Data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China). |
Q44998853 | Intravenous thrombolysis outcomes in patients presenting with large vessel acute ischemic strokes--CT angiography-based prognosis |
Q33698627 | Intravenous thrombolytic therapy for stroke: a review of recent studies and controversies |
Q35648096 | Intravenous thrombolytics for ischemic stroke |
Q60221610 | Intérêt de la TDM de perfusion dans le diagnostic d’un AVC ischémique sylvien à la phase précoce |
Q86090700 | In Vitro Examination of the Thrombolytic Efficacy of Desmoteplase and Therapeutic Ultrasound Compared with rt-PA |
Q40531467 | Is acute reperfusion therapy safe in acute ischemic stroke patients who harbor unruptured intracranial aneurysm? |
Q33529160 | Is atrial fibrillation associated with poor outcome after thrombolysis? |
Q38038053 | Is general anaesthesia preferable to conscious sedation in the treatment of acute ischaemic stroke with intra-arterial mechanical thrombectomy? A review of the literature |
Q88302804 | Is the Efficacy of Endovascular Treatment for Acute Ischemic Stroke Sex-Related |
Q34037933 | Is the NIHSS certification process too lenient? |
Q34566651 | Is the promise of randomized control trials ("evidence-based medicine") overstated? |
Q57812836 | Ischaemic Stroke and Transient Ischaemic Attack |
Q90640005 | Ischaemic stroke |
Q34037705 | Ischemic penumbra: evidence from functional imaging in man. |
Q37895311 | Ischemic stroke--novel therapeutic strategies |
Q35940947 | Iterative Reconstruction Improves Both Objective and Subjective Image Quality in Acute Stroke CTP. |
Q58599105 | Knowledge and Attitudes of Saudi Emergency Physicians toward t-PA Use in Stroke |
Q47101474 | LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH. |
Q37134651 | Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated |
Q90698741 | Legal medicine implications in fibrinolytic therapy of acute ischemic stroke |
Q48132154 | Leptin/adiponectin ratio predicts poststroke neurological outcome |
Q55176428 | Leukoaraiosis and risk of intracranial hemorrhage and outcome after stroke thrombolysis. |
Q39076189 | Leukoaraiosis is a predictor of futile recanalization in acute ischemic stroke. |
Q35502996 | Leukoaraiosis on magnetic resonance imaging is related to long-term poor functional outcome after thrombolysis in acute ischemic stroke |
Q33539477 | Limiting neurological damage after stroke: a review of pharmacological treatment options |
Q46704364 | Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. |
Q39402189 | Locally Deliver the Tissue-Type Plasminogen Activator (tPA) Plasmid for Preventing Thrombosis |
Q37041080 | Long-term outcomes of acute ischemic stroke in patients aged 80 years and older |
Q43702546 | Long-term outcomes of post-thrombolytic intracerebral hemorrhage in ischemic stroke patients |
Q64999053 | Low Cholesterol Levels Increase Symptomatic Intracranial Hemorrhage Rates After Intravenous Thrombolysis: A Multicenter Cohort Validation Study. |
Q54966172 | Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients. |
Q47103883 | Low free triiodothyronine levels predict symptomatic intracranial hemorrhage and worse short-term outcome of thrombolysis in patients with acute ischemia stroke |
Q48154216 | Low glomerular filtration rate increases hemorrhagic transformation in acute ischemic stroke |
Q92900436 | Low triiodothyronine syndrome is associated with hemorrhagic transformation in patients with acute ischaemic stroke |
Q37624269 | Low-Dose Versus Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Meta-Analysis |
Q28222300 | Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study |
Q31110396 | MR and CT perfusion imaging of the brain: principles and clinical applications |
Q37317803 | MR mismatch profiles in patients with intracranial atherosclerotic stroke: a comprehensive approach comparing stroke subtypes |
Q33922434 | MR perfusion imaging in acute ischemic stroke. |
Q62779438 | MRI patient selection for endovascular thrombectomy in acute ischemic stroke: correlation between pretreatment diffusion weighted imaging and outcome scores |
Q90100116 | MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS |
Q34132045 | MRI-guided selection of patients for treatment of acute ischemic stroke. |
Q35696214 | MRI-guided therapy in acute stroke |
Q34357599 | Magnetic resonance imaging in acute ischemic stroke treatment |
Q24239967 | Magnetic resonance imaging versus computed tomography for detection of acute vascular lesions in patients presenting with stroke symptoms |
Q30411823 | Magnetic resonance-guided focused ultrasound surgery: Part 2: A review of current and future applications |
Q26796470 | Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications |
Q38763038 | Management of acute ischaemic stroke in patients with dementia |
Q34370469 | Management of acute ischaemic stroke in the elderly: tolerability of thrombolytics |
Q33949713 | Management of acute ischemic stroke. What is the role of tPA and antithrombotic agents? |
Q30431467 | Management of ischaemic stroke in the acute setting: review of the current status |
Q57183611 | Management of patients with stroke treated with direct oral anticoagulants |
Q84959671 | Mean platelet volume predicting carotid atherosclerosis in atherothrombotic ischemic stroke |
Q36310421 | Mechanical Recanalization following i.v. Thrombolysis: A Retrospective Analysis regarding Secondary Hemorrhagic Infarctions and Parenchymal Hematomas |
Q53058924 | Mechanical Thrombectomy in Acute Occlusion of the Carotid-T: A Retrospective Single Centre Study in 51 Patients. |
Q55449290 | Mechanical Thrombectomy in Strokes with Large-Vessel Occlusion Beyond 6 Hours: A Pooled Analysis of Randomized Trials. |
Q40350754 | Mechanical Thrombectomy of Distal Occlusions in the Anterior Cerebral Artery: Recanalization Rates, Periprocedural Complications, and Clinical Outcome. |
Q33223665 | Mechanical recanalization for acute ischemic stroke |
Q43232072 | Mechanical recanalization in ischemic anterior circulation stroke within an 8-hour time window: a real-world experience |
Q41257786 | Mechanical thrombectomy for acute ischemic stroke : current evidence and open questions |
Q37732255 | Mechanical thrombectomy for the treatment of acute ischemic stroke |
Q35610113 | Medical management of patients with an acute stroke: treatment and prevention |
Q34187207 | Medical management of stroke |
Q34271952 | Medical therapy for acute ischemic stroke |
Q34522800 | Merci Retriever in acute stroke treatment |
Q37269853 | Methodology of acute trials in stroke |
Q40060158 | Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial |
Q39982266 | Midterm clinical and angiographic follow-up for the first Food and Drug Administration-approved prospective, Single-Arm Trial of Primary Stenting for Stroke: SARIS (Stent-Assisted Recanalization for Acute Ischemic Stroke). |
Q34683816 | Migraine and functional outcome from ischemic cerebral events in women |
Q38837575 | Minor Stroke Syndromes in Large-Vessel Occlusions: Mechanical Thrombectomy or Thrombolysis Only? |
Q37005689 | Mismatch of Low Perfusion and High Permeability Predicts Hemorrhagic Transformation Region in Acute Ischemic Stroke Patients Treated with Intra-arterial Thrombolysis |
Q97425313 | Missing outcome data management in acute stroke trials testing iv thrombolytics. Is there risk of bias? |
Q34538611 | Mobilization after thrombolysis (rtPA) within 24 hours of acute stroke: what factors influence inclusion of patients in A Very Early Rehabilitation Trial (AVERT)? |
Q30497328 | Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales |
Q37711254 | Modeling stroke management: a qualitative review of cost-effectiveness analyses |
Q36297789 | Modified ASPECTS for DWI including deep white matter lesions predicts subsequent intracranial hemorrhage |
Q47303075 | Monocyte count at onset predicts poststroke outcomes during a 90-day follow-up. |
Q50091286 | Mortality and Disability According to Baseline Blood Pressure in Acute Ischemic Stroke Patients Treated by Thrombectomy: A Collaborative Pooled Analysis. |
Q57895497 | Mortality in patients treated by intra-venous thrombolysis for ischaemic stroke |
Q88720812 | Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke |
Q38103827 | Multisociety consensus quality improvement guidelines for intraarterial catheter-directed treatment of acute ischemic stroke, from the American Society of Neuroradiology, Canadian Interventional Radiology Association, Cardiovascular and Intervention |
Q92955595 | Neurocognitive and functional impairment in adult and paediatric tuberculous meningitis |
Q81351763 | Neuroimaging in acute stroke |
Q30810278 | Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy |
Q33673824 | Neurologic complications in the intensive care unit |
Q40123556 | Neuroprotection and the ischemic cascade |
Q44318931 | Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy |
Q38152663 | Neurothrombectomy in the treatment of acute ischaemic stroke |
Q36331049 | New goals in ischemic stroke therapy: the experimental approach--harmonizing science with practice. |
Q34566330 | New insights on thrombolytic treatment of acute ischemic stroke |
Q37673214 | Non-steroidal anti-inflammatory drug use and functional outcome from ischemic cerebral events among women |
Q37579315 | Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator |
Q49689017 | Novel Telestroke Program Improves Thrombolysis for Acute Stroke Across 21 Hospitals of an Integrated Healthcare System |
Q37207243 | Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke? |
Q48068167 | One-year MR angiographic and clinical follow-up after intracranial mechanical thrombectomy using a stent retriever device. |
Q37348177 | Onset of Orolingual Angioedema After Treatment of Acute Brain Ischemia with Alteplase Depends on the Site of Brain Ischemia: A Meta-analysis |
Q38006071 | Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and efficacy as standard dose |
Q34595105 | Optimal timing of thrombolytic therapy in acute ischaemic stroke |
Q34056969 | Optimizing prediction scores for poor outcome after intra-arterial therapy in anterior circulation acute ischemic stroke |
Q38019575 | Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA). |
Q44636590 | Organizational changes aiming to reduce iv tPA door-to-needle time |
Q36375658 | Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban |
Q34326883 | Outcome of ischemic stroke patients with serious post-thrombolysis neurological deficits |
Q57895512 | Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia |
Q33719200 | Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator |
Q38285447 | Outcomes after stroke thrombolysis according to prior antiplatelet use. |
Q24646395 | Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older |
Q36570639 | Outcomes of patients with large middle cerebral artery infarct treated with and without intravenous thrombolysis |
Q38489211 | Outcomes of stent retriever thrombectomy in basilar artery occlusion: an observational study and systematic review |
Q35104807 | Oxfordshire Community Stroke Project classification improves prediction of post-thrombolysis symptomatic intracerebral hemorrhage |
Q37083630 | Past, present and future of alteplase for acute ischemic stroke. |
Q34574766 | Pathophysiology of acute middle cerebral artery infarct by multimodal computed tomography: A pilot study in Thai patients |
Q36496980 | Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. |
Q59136921 | Patients With Ischemic Core ≥70 ml Within 6 h of Symptom Onset May Still Benefit From Endovascular Treatment |
Q37133844 | Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study. |
Q34107379 | Patients with acute stroke: recent developments in neuroimaging |
Q45809829 | Penumbra system: a novel mechanical thrombectomy device for large-vessel occlusions in acute stroke. |
Q43513962 | Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia |
Q84639111 | Percutaneous Balloon Angioplasty for Acute Occlusion of Intracranial Arteries |
Q83506331 | Percutaneous transluminal angioplasty and stent placement in acute vessel occlusion: evaluation of new methods for interventional stroke treatment |
Q48146426 | Perfusion CT in acute stroke: prediction of vessel recanalization and clinical outcome in intravenous thrombolytic therapy |
Q35113503 | Perfusion CT: a worthwhile enhancement? |
Q53210064 | Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo-controlled, pilot feasibility trial. |
Q60483545 | Perfusion-Weighted MRI in Human Acute Ischemic Stroke |
Q55096016 | Periprocedural Antithrombotic Treatment During Acute Mechanical Thrombectomy for Ischemic Stroke: A Systematic Review. |
Q30652275 | Periprocedural aspects in mechanical recanalization for acute stroke: data from the ENDOSTROKE registry |
Q35608208 | Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke |
Q38610670 | Pharmacokinetic and metabolomic analyses of the neuroprotective effects of salvianolic acid A in a rat ischemic stroke model |
Q37024492 | Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly |
Q36662909 | Pharmacotherapy considerations in advanced cardiac life support |
Q37514167 | Pharmacotherapy of cerebral ischemia |
Q35660646 | Physiologic imaging in acute stroke: Patient selection. |
Q35676660 | Placebo and the Helsinki Declaration--what to do? |
Q37998537 | Plasminogen activation and thrombolysis for ischemic stroke |
Q36988667 | Plasminogen activators and ischemic stroke: conditions for acute delivery |
Q93003738 | Post-Stroke Blood-Brain Barrier Disruption and Poor Functional Outcome in Patients Receiving Thrombolytic Therapy |
Q90400706 | Post-hoc Analysis of Outcome of Intravenous Thrombolysis in Infarcts of Infratentorial Localization in the WAKE-UP Trial |
Q47713661 | Post-thrombolytic blood pressure and symptomatic intracerebral hemorrhage. |
Q88141734 | Posterior Circulation Occlusions May Be Associated with Distal Emboli During Thrombectomy : Factors for Distal Embolization and a Review of the Literature |
Q41449671 | Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of hemorrhage after thrombolysis. |
Q47711814 | Poststroke infections are an independent risk factor for poor functional outcome after three-months in thrombolysed stroke patients |
Q36130124 | Postthrombolytic Antiplatelet Use for Patients with Intercerebral Hemorrhage without Extensive Parenchymal Involvement Does Not Worsen Outcome |
Q39447215 | Potential biomarkers for predicting hemorrhagic transformation of ischemic stroke |
Q34061211 | Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications |
Q73740291 | Potential role of abciximab in ischemic cerebrovascular disease |
Q31145197 | Power of an Adaptive Trial Design for Endovascular Stroke Studies: Simulations Using IMS (Interventional Management of Stroke) III Data. |
Q38639109 | Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model |
Q26830834 | Predicting a post-thrombolysis intracerebral hemorrhage: a systematic review |
Q34722493 | Predicting intracerebral hemorrhage by baseline magnetic resonance imaging in stroke patients undergoing systemic thrombolysis |
Q41702122 | Predicting risk of symptomatic intracerebral hemorrhage and mortality after treatment with recombinant tissue-plasminogen activator using SEDAN score |
Q47808481 | Predicting spontaneous early neurological recovery after acute ischemic stroke. |
Q43829243 | Prediction of hemorrhagic transformation in acute ischaemic stroke by micro- and macroalbuminuria after intravenous thrombolysis |
Q33709879 | Prediction of two month modified Rankin Scale with an ordinal prediction model in patients with aneurysmal subarachnoid haemorrhage |
Q48136162 | Predictive value of flat-panel CT for haemorrhagic transformations in patients with acute stroke treated with thrombectomy. |
Q64951255 | Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator. |
Q90680781 | Predictors of Outcome After Endovascular Thrombectomy in Acute Basilar Artery Occlusion and the 6hr Time Window to Recanalization |
Q35862442 | Predictors of Outcome and Hemorrhage in Patients Undergoing Endovascular Therapy with Solitaire Stent for Acute Ischemic Stroke |
Q37683678 | Predictors of Outcome following Stroke due to Isolated M2 Occlusions |
Q52999162 | Predictors of a Good Outcome after Endovascular Stroke Treatment with Stent Retrievers. |
Q33624072 | Predictors of good clinical outcome in acute stroke patients treated with intravenous thrombolysis |
Q44388212 | Predictors of hemorrhage following intra-arterial thrombolysis for acute ischemic stroke: the role of pial collateral formation |
Q51737433 | Preliminary study of time maximum intensity projection computed tomography imaging for the detection of early ischemic change in patient with acute ischemic stroke. |
Q88047087 | Presence of multi-segment clot sign on dynamic CT angiography: a predictive imaging marker of recanalisation and good outcome in acute ischaemic stroke patients |
Q35848283 | Prestroke dementia is associated with poor outcomes after reperfusion therapy among elderly stroke patients. |
Q34171137 | Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis |
Q89864495 | Prevalence of a Multiple Territory Stroke Pattern After Intravenous Thrombolysis |
Q57826355 | Prevalence of disabling spasticity 1 year after first-ever stroke |
Q37738247 | Primary intracranial stenting in acute ischemic stroke |
Q90115520 | Professional guideline versus product label selection for treatment with IV thrombolysis: An analysis from SITS registry |
Q58127014 | Prognostic Significance of Pulse Pressure Variability During Mechanical Thrombectomy in Acute Ischemic Stroke Patients |
Q48215223 | Prognostic significance of proteinuria in stroke patients treated with intravenous thrombolysis. |
Q93073777 | Prognostic value of subclinical thyroid dysfunction in ischemic stroke patients treated with intravenous thrombolysis |
Q45005569 | Prolonged low-dose thrombolysis in posterior circulation stroke |
Q34826078 | Quantification of errors in ordinal outcome scales using shannon entropy: effect on sample size calculations |
Q100415962 | Quantified ischemic core's radiological hypodensity and risk of parenchymal hematoma in > 4.5 h-window stroke thrombectomy |
Q35013712 | RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study |
Q81098199 | Randomized comparison of intra-arterial and intravenous thrombolysis in a canine model of acute basilar artery thrombosis |
Q53288461 | Rapid Reconstitution Packages (RRPs) implemented by integration of computational fluid dynamics (CFD) and 3D printed microfluidics. |
Q44135056 | Rates and outcomes of neurosurgical treatment for postthrombolytic intracerebral hemorrhage in patients with acute ischemic stroke |
Q93188834 | Real-World Thrombectomy Using the Sofia Catheter |
Q33886064 | Reasons and evolution of non-thrombolysis in acute ischaemic stroke. |
Q64977754 | Reasons for delayed admission after stroke: results of a qualitative and quantitative survey. |
Q30479878 | Recanalization Therapies in Acute Ischemic Stroke: Pharmacological Agents, Devices, and Combinations |
Q37812281 | Recanalization therapy for acute ischemic stroke, part 1: surgical embolectomy and chemical thrombolysis |
Q64984610 | Recanalization treatments in basilar artery occlusion-Systematic analysis. |
Q37844469 | Recent advances in magnetic resonance imaging in posterior circulation stroke: implications for diagnosis and prognosis |
Q30626736 | Recent advances in the diagnosis and treatment of stroke |
Q24595703 | Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis |
Q48492153 | Recombinant tissue plasminogen activator increases blood-brain barrier disruption in acute ischemic stroke: an MR imaging permeability study |
Q35019813 | Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis |
Q31153077 | Recommendations and treatment strategies for the management of acute ischemic stroke. |
Q43725353 | Reduced risk of poststroke pneumonia in thrombolyzed stroke patients with continued statin treatment |
Q36831052 | Reducing haemorrhagic transformation after thrombolysis for stroke: a strategy utilising minocycline |
Q48854658 | Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat. |
Q48793652 | Referral and care for acute ischemic stroke in a Japanese tertiary emergency hospital |
Q47178043 | Regional Differences in Thrombectomy Rates : Secondary use of Billing Codes in the MIRACUM (Medical Informatics for Research and Care in University Medicine) Consortium. |
Q57173837 | Related Research and Recent Progress of Ischemic Penumbra |
Q36289929 | Relation between reperfusion and hemorrhagic transformation in acute ischemic stroke |
Q51065952 | Relationship between hospital volume and early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. |
Q38950763 | Relationship of functional disability after a recent stroke with recurrent stroke risk |
Q34038281 | Relationship of neurovascular elements to neuron injury during ischemia |
Q35554576 | Reperfusion of very low cerebral blood volume lesion predicts parenchymal hematoma after endovascular therapy. |
Q37898340 | Reperfusion strategies for acute ischemic stroke |
Q90157955 | Reperfusion therapy for minor stroke: A systematic review and meta-analysis |
Q47861990 | Reperfusion therapy in acute ischemic stroke: dawn of a new era? |
Q37476191 | Reperfusion-associated hemorrhagic transformation in SHR rats: evidence of symptomatic parenchymal hematoma |
Q52996663 | Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. |
Q37776325 | Reversibility of Ischemia Evaluated by Ischemic Duration and Residual Cerebral Blood Flow |
Q30248290 | Review article: Why is there still a debate regarding the safety and efficacy of intravenous thrombolysis in the management of presumed acute ischaemic stroke? A systematic review and meta-analysis |
Q31108632 | Review of the current status of intra-arterial thrombolysis for treating acute cerebral infarction: a retrospective analysis of the data from multiple centers in Korea |
Q55442475 | Review: Clinical application of diffusion tensor imaging. |
Q48872792 | Rightward bias in right hemisphere infarct patients with or without thrombolytic treatment and in healthy controls |
Q89620583 | Risk Factors for Epilepsy After Thrombolysis for Ischemic Stroke: A Cohort Study |
Q22306325 | Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Systematic Review and Meta-Analysis of 55 Studies |
Q38726835 | Risk of Intracranial Hemorrhage after Endovascular Treatment for Acute Ischemic Stroke: Systematic Review and Meta-Analysis |
Q31107456 | Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis |
Q37274254 | Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis |
Q34948774 | Risks and benefits of early antithrombotic therapy after thrombolytic treatment in patients with acute stroke |
Q37977532 | Risks and benefits of thrombolysis in the elderly |
Q37850893 | Role of tissue plasminogen activator in acute ischemic stroke |
Q44792514 | Routine serum C-reactive protein and stroke outcome after intravenous thrombolysis. |
Q35472072 | S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion |
Q46360147 | SOLITAIRE™ with the intention for thrombectomy (SWIFT) trial: design of a randomized, controlled, multicenter study comparing the SOLITAIRE™ Flow Restoration device and the MERCI Retriever in acute ischaemic stroke |
Q44197349 | Safe implementation of thrombolysis in stroke-monitoring study in Italy. |
Q39648908 | Safety and Effectiveness of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in 80 Years and Older Acute Ischemic Stroke Patients |
Q37202149 | Safety and efficacy of alteplase in the treatment of acute ischemic stroke |
Q34669641 | Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial |
Q46226330 | Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. |
Q38075828 | Safety and efficacy of thrombolysis with intravenous alteplase in older stroke patients |
Q50702011 | Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. |
Q41344390 | Safety of intravenous thrombolysis for acute ischaemic stroke including concomitant neoplastic disease sufferers - experience from Poland |
Q48277692 | Safety of intravenous thrombolysis for acute ischemic stroke in patients with preexisting intracranial neoplasms: a case series |
Q47107691 | Safety of thrombolysis in stroke mimics: an observational cohort study from an urban teaching hospital in Sweden. |
Q64232702 | Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms |
Q35802651 | Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice |
Q34538232 | Selection for delayed intravenous alteplase treatment based on a prognostic score |
Q59812734 | Serum lipid level is not associated with symptomatic intracerebral hemorrhage after intravenous thrombolysis for acute ischemic stroke |
Q41353520 | Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke |
Q39061399 | Severe cerebral hypovolemia on perfusion CT and lower body weight are associated with parenchymal haemorrhage after thrombolysis. |
Q73959725 | Severe intracranial hemorrhage after emergency carotid stenting and abciximab administration for postoperative thrombosis |
Q38302755 | Should minor stroke patients be thrombolyzed? A focused review and future directions. |
Q42093118 | Should physicians give tPA to patients with acute ischemic stroke? Against: and just what is the emperor of stroke wearing? |
Q83816438 | Should the Window for Intravenous Administration of Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke be Extended to 4.5 Hours? |
Q50439631 | Significance of Development and Reversion of Collaterals on MRI in Early Neurologic Improvement and Long-Term Functional Outcome after Intravenous Thrombolysis for Ischemic Stroke |
Q83255927 | Skepticism about thrombolytics in stroke is not unreasonable |
Q61649814 | Snake venom, vampire bat saliva, or rt-PA: time matters |
Q44131035 | Solitaire Flow Restoration thrombectomy for acute ischemic stroke: retrospective multicenter analysis of early postmarket experience after FDA approval |
Q36654730 | Spontaneous Splenic Rupture Following Intravenous Thrombolysis with Alteplase Applied as Stroke Therapy - Case Report and Review of Literature |
Q87173838 | Stability of ischemic core volume during the initial hours of acute large vessel ischemic stroke in a subgroup of mechanically revascularized patients |
Q46106913 | Statement of ESMINT and ESNR regarding recent trials evaluating the endovascular treatment at the acute stage of ischemic stroke. |
Q49151358 | Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis |
Q39393871 | Status of endovascular interventions to treat acute ischemic stroke |
Q92542471 | Stent Retriever Thrombectomy Potentially Increases the Recanalization Rate, Improves Clinical Outcome, and Decreases Mortality in Acute Basilar Occlusion: A Systematic Review and Meta-Analysis |
Q41564022 | Stent Retriever Thrombectomy of Small Caliber Intracranial Vessels Using pREset LITE: Safety and Efficacy |
Q44579507 | Stent retrievers in acute ischemic stroke: complications and failures during the perioperative period. |
Q38809990 | Stent-Retriever Thrombectomy for Acute Anterior Ischemic Stroke with Tandem Occlusion: A Systematic Review and Meta-Analysis. |
Q38951472 | Stop Stroke: A Brief Report on Door-to-Needle Times and Performance After Implementing an Acute Care Coordination Medical Application and Implications to Emergency Medical Services |
Q38117170 | Strategies to improve recovery in acute ischemic stroke patients: Iberoamerican Stroke Group Consensus |
Q36659436 | Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100 |
Q47810106 | Stroke attributable to acute basilar occlusion. |
Q42370120 | Stroke mimic: Perfusion magnetic resonance imaging of a patient with ictal paralysis |
Q37098053 | Stroke pathophysiology: management challenges and new treatment advances. |
Q42270352 | Stroke penumbra defined by an MRI-based oxygen challenge technique: 1. Validation using [14C]2-deoxyglucose autoradiography. |
Q30151101 | Stroke preparedness in children: translating knowledge into behavioral intent: a systematic review and meta-analysis. |
Q34037169 | Stroke thrombolysis: is tissue plasminogen activator a defibrillator for the brain? |
Q48426796 | Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial |
Q28166505 | Stroke, dementia, and drug delivery |
Q51160184 | Stroke- on- Awakening: Safety of CT-CTA Based Selection for Reperfusion Therapy. |
Q43102060 | Successful outcome after endovascular thrombolysis for acute ischemic stroke even after 24 h of symptoms onset? |
Q36134874 | Successful recanalization post endovascular therapy is associated with a decreased risk of intracranial haemorrhage: a retrospective study |
Q34439225 | Successful use of Alteplase during cardiopulmonary resuscitation following massive PE in a patient presenting with ischaemic stroke and haemorrhagic transformation. |
Q40110062 | Surgical embolectomy for large vessel occlusion of anterior circulation |
Q48140724 | Susceptibility Vessel Sign on MRI Predicts Favorable Clinical Outcome in Patients with Anterior Circulation Acute Stroke Treated with Mechanical Thrombectomy. |
Q36118307 | Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment |
Q53674730 | Symptomatic intracranial haemorrhage after thrombolysis with adjuvant anticoagulation in basilar artery occlusion. |
Q34241228 | Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score |
Q89357288 | Symptomatic periprocedural intracranial hemorrhage unrelated to coil embolization in 1287 patients with intracranial aneurysms |
Q39425519 | Symptomatic post-thrombolytic intracerebral hemorrhage is not related to the cause of stroke. |
Q36986430 | Systemic reperfusion therapy in acute ischemic stroke. |
Q47880979 | Systolic Blood Pressure Variability is Associated with Severe Hemorrhagic Transformation in the Early Stage After Thrombolysis |
Q42634449 | TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours a |
Q48785641 | TOAST criteria applied in acute ischemic stroke |
Q46891457 | TPA use for stroke in the Registry of the Canadian Stroke Network. |
Q40572133 | TURN Score Predicts 24-Hour Cerebral Edema After IV Thrombolysis. |
Q40880627 | TURN Score Predicts 90-day Outcome in Acute Ischemic Stroke Patients After IV Thrombolysis. |
Q41079114 | TURN: A Simple Predictor of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis. |
Q91667637 | Technical and Clinical Outcomes After Thrombectomy for the Various Segments of the Middle Cerebral Artery |
Q55008330 | Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country-Nepal: Cost, Efficacy, and Safety. |
Q30277030 | Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials |
Q48436630 | Texture analysis of computed tomography images of acute ischemic stroke patients |
Q37599917 | The Alberta Stroke Program Early CT Score in clinical practice: what have we learned? |
Q35055490 | The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis |
Q37057182 | The Basilar Artery International Cooperation Study (BASICS): study protocol for a randomised controlled trial |
Q42279127 | The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke |
Q35627094 | The Comparison of Outcome between Thromboaspiration and Aggressive Mechanical Clot Disruption in Treating Hyperacute Stroke Patients |
Q40642515 | The Effect of External Ventricular Drain Use in Intracerebral Hemorrhage |
Q47191663 | The Impact of Discrepancy between Measured versus Stated Weight on Hemorrhagic Transformation and Clinical Outcomes after Intravenous Alteplase Thrombolysis |
Q89536709 | The Impact of Loading Dose on Outcome in Stroke Patients Receiving Low-Dose Tissue Plasminogen Activator Thrombolytic Therapy |
Q52599324 | The Influence of Sex in Stroke Thrombolysis: A Systematic Review and Meta-Analysis. |
Q39063099 | The Italian Registry of Endovascular Treatment in Acute Stroke: rationale, design and baseline features of patients. |
Q51049722 | The Merci Retrieval System for acute stroke: the Southeast Regional Stroke Center experience. |
Q94028792 | The Potential Impact of Maintaining a 3-Hour IV Thrombolysis Window: How Many More Patients can we Safely Treat? |
Q92275626 | The Risk of Symptomatic Intracranial Hemorrhage after Thrombolysis for Acute Stroke: Current Concepts and Perspectives |
Q94602841 | The Safety and Efficiency of Tirofiban in Acute Ischemic Stroke Patients Treated with Mechanical Thrombectomy: A Multicenter Retrospective Cohort Study |
Q35209739 | The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST. |
Q35848802 | The ThRombolysis in UnconTrolled Hypertension (TRUTH) protocol: an observational study on treatment strategy of elevated blood pressure in stroke patients eligible for IVT |
Q38416663 | The Virtual International Stroke Trials Archive (VISTA): results and impact on future stroke trials and management of stroke patients |
Q48321926 | The anti-inflammatory effect of paeoniflorin on cerebral infarction induced by ischemia-reperfusion injury in Sprague-Dawley rats |
Q35786086 | The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. |
Q89547256 | The association between monocyte to high-density lipoprotein ratio and hemorrhagic transformation in patients with acute ischemic stroke |
Q40058955 | The basilar artery international cooperation study (BASICS). |
Q97531248 | The clinical conundrum of managing ischemic stroke in patients with immune thrombocytopenia |
Q47683094 | The development of stroke services: entering the new millennium |
Q51012339 | The effect of thrombolysis on short-term improvement depends on initial stroke severity. |
Q48783061 | The effectiveness of thrombolysis with intravenous alteplase for acute ischemic stroke in daily practice |
Q48224063 | The efficacy of thrombolysis in lacunar stroke - evidence from the Austrian Stroke Unit Registry |
Q33566798 | The evolution of transcranial laser therapy for acute ischemic stroke, including a pooled analysis of NEST-1 and NEST-2 |
Q33716599 | The golden hour of acute ischemic stroke |
Q34075316 | The impact of early specialist management on outcomes of patients with in-hospital stroke |
Q37696584 | The neurovascular unit in the setting of stroke |
Q34635173 | The outcome of patients with mild stroke improves after treatment with systemic thrombolysis |
Q35476867 | The probability of middle cerebral artery MRA flow signal abnormality with quantified CT ischaemic change: targets for future therapeutic studies |
Q45939202 | The proposed 'concordance-statistic for benefit' provided a useful metric when modeling heterogeneous treatment effects. |
Q37017597 | The quest for arterial recanalization in acute ischemic stroke-the past, present and the future. |
Q48254861 | The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation |
Q33853254 | The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm. |
Q36412737 | The role of additional computed tomography in the decision-making process on the secondary prevention in patients after systemic cerebral thrombolysis |
Q40839819 | The role of perfusion CT in identifying stroke mimics in the emergency room: a case of status epilepticus presenting with perfusion CT alterations |
Q35943820 | The safety and effectiveness of low-dose recombinant tissue plasminogen activator (0.6 mg/kg) therapy for elderly acute ischemic stroke patients (≥ 80 years old) in the pre-endovascular era |
Q37554499 | The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke |
Q48840325 | The serum ferritin level is an important predictor of hemorrhagic transformation in acute ischaemic stroke |
Q39985481 | The smoking paradox: impact of smoking on recanalization in the setting of intra-arterial thrombolysis |
Q47737649 | The use of PWI and DWI measures in the design of "proof-of-concept" stroke trials |
Q30749058 | The very acute stroke treatment: fibrinolysis and after |
Q30499139 | Therapeutic advances in interventional neurology |
Q30938168 | Therapeutic time window of thrombolytic therapy following stroke |
Q38764867 | Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke |
Q64227938 | Therapy for acute basilar artery occlusion: a systematic review and meta-analysis |
Q28210949 | Therapy for early reperfusion after stroke |
Q36742130 | Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke |
Q42907046 | Thrombi of Different Pathologies: Implications for Diagnosis and Treatment |
Q38198740 | Thrombolysis and reperfusion: advanced understanding of early management strategies in acute ischemic stroke |
Q47924174 | Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion |
Q24194788 | Thrombolysis for acute ischaemic stroke |
Q24240067 | Thrombolysis for acute ischaemic stroke |
Q24247962 | Thrombolysis for acute ischaemic stroke |
Q42668646 | Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). |
Q48139385 | Thrombolysis for acute ischemic stroke: does it work?--the con position |
Q33938946 | Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study |
Q33794859 | Thrombolysis for acute stroke |
Q34107350 | Thrombolysis for acute stroke: is it for everyone? |
Q31109436 | Thrombolysis for ischemic stroke: an update |
Q53571708 | Thrombolysis for stroke in the elderly. |
Q83376792 | Thrombolysis for stroke: policy should be based on science, and not on politics, money or fear of malpractice |
Q92601645 | Thrombolysis in Cerebral Infarction Grade 2C or 3 Represents a Better Outcome than 2B for Endovascular Thrombectomy in Acute Ischemic Stroke: A Network Meta-Analysis |
Q34164541 | Thrombolysis in acute ischaemic stroke |
Q33217342 | Thrombolysis in acute ischaemic stroke: a guide to patient selection |
Q40696300 | Thrombolysis in acute ischemic stroke is associated with lower long-term hospital bed day use: A nationwide propensity score-matched follow-up study. |
Q35631279 | Thrombolysis in chinese ischemic stroke patients with renal dysfunction |
Q34143581 | Thrombolysis in ischemic strokes with no arterial occlusion |
Q36226503 | Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study |
Q77466547 | Thrombolysis in stroke beyond three hours: Targeting patients with diffusion and perfusion MRI |
Q38075577 | Thrombolysis in the developing world: is there a role for streptokinase? |
Q48552966 | Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy |
Q45974947 | Thrombolysis on ischemic stroke patients with decreased level of consciousness within 4.5 h. |
Q34561985 | Thrombolysis risk prediction: applying the SITS-SICH and SEDAN scores in South African patients |
Q37879682 | Thrombolysis treatment for acute stroke: issues of efficacy and utilization in women |
Q81963102 | Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study |
Q42610437 | Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. |
Q36870040 | Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies |
Q33646036 | Thrombolysis, stroke units and other strategies for reducing acute stroke costs. |
Q37571432 | Thrombolysis, stroke-unit admission and early rehabilitation in elderly patients |
Q48294695 | Thrombolytic Therapy in Acute Ischemic Stroke |
Q31156580 | Thrombolytic Treatment for Ischaemic Stroke: Could the Crisis of Confidence Have Been Avoided by Better Analysis of Trial Data? |
Q73521065 | Thrombolytic properties of leukocytes from peripheral blood in healthy subjects and in patients with acute cerebral ischemia |
Q36227021 | Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome |
Q77939627 | Thrombolytic therapy for acute ischemic stroke |
Q78022218 | Thrombolytic therapy for acute ischemic stroke |
Q35552867 | Thrombolytic therapy for acute ischemic stroke beyond three hours |
Q36106814 | Thrombolytic therapy for acute ischemic stroke: 3 h and beyond |
Q81969469 | Thrombolytic therapy for acute stroke |
Q33632565 | Thrombolytic therapy for acute stroke in Austria: data from the Safe Implementation of Thrombolysis in Stroke (SITS) register |
Q33398481 | Thrombolytic therapy for patients who wake-up with stroke |
Q33873285 | Thrombolytic therapy for stroke: a review with particular reference to elderly patients. |
Q36472612 | Thrombolytic therapy in pregnancy |
Q35081866 | Thrombolytic therapy: clinical applications |
Q36254835 | Thrombolytic treatment of acute cerebral infarction |
Q31029314 | Thrombolytic-Related Asymptomatic Hemorrhagic Transformation Does Not Deteriorate Clinical Outcome: Data from TIMS in China |
Q47941678 | Time for a Time Window Extension: Insights from Late Presenters in the ESCAPE Trial |
Q48829887 | Time to hospital admission and start of treatment in patients with ischemic stroke in northern Italy and predictors of delay |
Q39933423 | Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials |
Q51626282 | Timing of Symptomatic Infarct Swelling Following Intravenous Thrombolysis in Acute Middle Cerebral Artery Infarction: A Case-Control Study. |
Q56336828 | Tissue-type plasminogen activator as a therapeutic target in stroke |
Q40207994 | To Treat or Not to Treat M2 Occlusions? The Question (and Answer) From a Single Institution |
Q37605386 | Total time of operation is a risk factor of stroke-associated pneumonia in acute ischemic stroke patients with intra-arterial treatment |
Q37409117 | Translating research into practice: lessons from trials of thrombolysis in acute stroke. |
Q28196628 | Treating the acute stroke patient as an emergency: current practices and future opportunities |
Q45799384 | Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study |
Q38543305 | Treatment of acute ischemic stroke: from fibrinolysis to neurointervention |
Q37451515 | Treatment of acute ischemic stroke: intravenous and endovascular therapies |
Q40063905 | Treatment of acute ischemic stroke: systemic or local? |
Q48473559 | Treatment of acute stroke: a misconception |
Q38541197 | Treatment of acute stroke: an update |
Q80852679 | Treatment of cerebellar masses |
Q33897269 | Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. |
Q41588199 | Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways |
Q53135352 | Treatment with tPA predicts better outcome even if MCA occlusion persists. |
Q37584739 | Trends of the Incidence of Ischemic Stroke Thrombolysis over Seven Years and One-Year Outcome: A Population-Based Study in Joinville, Brazil |
Q26853103 | Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability |
Q80304426 | Ultra-early doppler sonography for stroke |
Q39532900 | Ultra-fast three-dimensional MR perfusion imaging of the entire brain in acute stroke assessment |
Q37244632 | Ultrasound enhanced thrombolysis for stroke. |
Q37176753 | Ultrasound enhanced thrombolysis in acute arterial ischemia. |
Q37203476 | Ultrasound enhanced thrombolysis: applications in acute cerebral ischemia |
Q48430318 | Ultrasound-enhanced thrombolysis for stroke: clinical significance |
Q36864308 | Ultrasound-enhanced thrombolysis in acute ischemic stroke: potential, failures, and safety |
Q39395552 | Update on Neurocritical Care of Stroke |
Q33956289 | Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice |
Q48558308 | Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke. |
Q34086851 | Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited |
Q53649850 | Use of CT angiography in patient selection for thrombolytic therapy. |
Q41635141 | Use of Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients: Evaluation of Clinical Outcomes |
Q35108125 | Use of antithrombotics after hemorrhagic transformation in acute ischemic stroke |
Q24793478 | Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials |
Q38078028 | Use of intravenous recombinant tissue plasminogen activator in patients outside the defined criteria: safety and feasibility issues |
Q37507984 | Use of neuroimaging in acute stroke trials |
Q48676504 | Usefulness of CT angiography for therapeutic decision making in thrombolyzing intubated patients with suspected basilar artery thrombosis. |
Q74033011 | Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score |
Q35152697 | Various blood glucose parameters that indicate hyperglycemia after intravenous thrombolysis in acute ischemic stroke could predict worse outcome |
Q42380288 | Visibility of CT Early Ischemic Change Is Significantly Associated with Time from Stroke Onset to Baseline Scan beyond the First 3 Hours of Stroke Onset |
Q34038274 | Wake-up stroke: clinical and neuroimaging characteristics |
Q38392999 | What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers. |
Q46768047 | What should be defined as good outcome in stroke trials; a modified Rankin score of 0-1 or 0-2? |
Q36533168 | Which model of stroke unit is better for stroke patient management? |
Q36245471 | Why have neuro-protectants failed?: lessons learned from stroke trials. |
Q55306230 | Why not Intravenous Thrombolysis in Patients with Recurrent Stroke within 3 Months? |
Q47223299 | Worse Outcome in Stroke Patients Treated with rt-PA Without Early Reperfusion: Associated Factors |
Q82060749 | [C-reactive protein in the acute phase of ischemic stroke] |
Q53375071 | [Computed tomography in acute ischemic stroke. Current developments compared with stroke MRI]. |
Q82958456 | [Current management of acute isquemic stroke] |
Q81691991 | [European Stroke Organisation 2008 guidelines for managing acute cerebral infarction or transient ischemic attack : part 2] |
Q74334263 | [Fibrinolytic treatment in acute cerebrovascular accident] |
Q81357386 | [Imaging of cerebral ischemia within first hours: computed tomography (CT)] |
Q82387389 | [Implementation of thrombolysis in acute stroke--10-year results of the Innsbruck stroke registry] |
Q81691889 | [Intra-arterial thrombolysis of the middle cerebral artery: an overview] |
Q53490659 | [Intravenous rt-PA for acute ischemic stroke: 69 consecutive patients managed in an emergency stroke centre] |
Q53662088 | [Intravenous tissue-type plasminogen activator for the treatment of acute cerebral ischemia]. |
Q81920598 | [Ischemic stroke in the elderly--analysis of the Austrian Stroke Unit Registry] |
Q82621794 | [Ischemic stroke patients following intravenous thrombolysis. Outcome in a regional stroke center] |
Q81703832 | [Recent studies concerning treatment of acute, ischemic infarcts] |
Q79928804 | [Recommendations of the European Stroke Initiative (EUSI) for treatment of ischemic stroke--update 2003. I. organization and acute therapy] |
Q83217445 | [Stroke MRI for risk assessment of intracerebral hemorrhage associated with thrombolytic therapy] |
Q80179571 | [Stroke and thrombolysis in a basic hospital. A possible duty] |
Q79331100 | [Treatment with intravenous rt-PA in a general hospital context: A review of the Saint-Jean Hospital experience from Perpignan, France] |
Q78784672 | [Unblocking arteries to save brains: thrombolysis in patients with stroke] |
Q53304411 | tPA treatment for acute ischaemic stroke in patients with leukoaraiosis. |
Search more.